深圳微芯生物科技股份有限公司自愿披露关于澳门药物监督管理局批准西达本胺上市的公告

Group 1 - The Macau Drug Regulatory Authority (ISAF) has approved the listing of Chidamide (brand name "Epidaza") by Shenzhen MicuRx Biopharma Co., Ltd [2] - Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and has been granted multiple indications in different regions, including peripheral T-cell lymphoma and breast cancer in mainland China, and adult leukemia and peripheral T-cell lymphoma in Japan [2] - The approval in Macau allows the company to expand its overseas market presence and enhance the market competitiveness of Chidamide [3]